ROCKVILLE, Md—The FDA’s Hematology and Pathology Devices Panel voted unanimously to recommend that the agency grant conditional approval to Vysis, Inc.’s PathVysion HER-2 DNA Probe Kit to detect and quantify the HER2 gene in breast cancer patients. Based on Vysis’ fluorescence in situ hybridization (FISH) technology, the test for the HER2 gene was developed as a predictive marker for determining a patient’s response to doxorubicin(Drug information on doxorubicin)-based chemotherapy.
|
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs Chastity Werner, RHIT, June 13, 2013 FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing. Improving Care Coordination in Your Practice Susanne Madden, June 12, 2013 Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help. Refunding Overpayments: Two Options for Medical Practices Ericka L. Adler, June 12, 2013 Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary. Four Easy Ways to Boost Patient Time of Service Collections Aubrey Westgate, June 12, 2013 Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments. iPad Alternatives for Mobile Physicians Marisa Torrieri, June 11, 2013 As more physicians are seeing the merits of media tablets, the market is expanding, too.
CancerNetwork on Facebook
|
|
CancerNetwork |
ConsultantLive |
Diagnostic Imaging |
Musculoskeletal Network |
OBGYN.net |
PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy